Escherichia coli: development of carbapenem resistance during therapy

Clin Infect Dis. 2005 May 15;40(10):e84-6. doi: 10.1086/429822. Epub 2005 Apr 13.

Abstract

A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Bacterial*
  • Escherichia coli / drug effects*
  • Escherichia coli / enzymology
  • Escherichia coli / genetics
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / microbiology*
  • Female
  • Humans
  • Imipenem / administration & dosage
  • Imipenem / pharmacology*
  • Imipenem / therapeutic use
  • Meropenem
  • Microbial Sensitivity Tests
  • Thienamycins / administration & dosage
  • Thienamycins / therapeutic use
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / microbiology

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • Imipenem
  • Meropenem